ArticleQuantitative imaging in medicine and surgery2025
Development of a prediction model for HER2 low breast cancer using quantitative intra- and peri-tumoral heterogeneity and MRI features on high-spatial resolution ultrafast DCE-MRI.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MRI-based habitat and peritumoral radiomics for predicting HER2 status in breast cancer: a multicenter study.Scientific reports · 2026Article
- Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate preoperative human epidermal growth factor receptor 2 (HER2) status assessment is crucial for guiding treatment selection, particularly with the emergence of anti-HER2 antibody-drug conjugates (ADCs) for HER2-low breast cancer. However, current immunohistochemistry (IHC)-based classification is limited by spatial heterogeneity and sampling bias. Quantitative analysis of intra- and peri-tumoral heterogeneity (ITH) on imaging may offer a non-invasive, objective, and reproducible approach to distinguish HER2-low breast cancer from other subtypes. This study aimed to investigate quantitative ITH from high-spatial resolution ultrafast dynamic contrast-enhanced magnetic resonance imaging (UF DCE-MRI) based kinetic curves in distinguishing HER2 low from HER2 zero or positive breast cancer. Methods: Consecutive breast cancer patients who underwent preoperative high-spatial-resolution UF DCE-MRI were retrospectively enrolled. They were stratified into HER2 zero, HER2 low, or HER2 positive groups based on IHC and in situ hybridization results. Traditional MRI findings and clinicopathological characteristics were evaluated, and personalized ITH scores were constructed using semi-quantitative parameters derived from kinetic curves. Models incorporating ITH, MRI, and clinicopathological distinctions were developed for dichotomized HER2 statuses prediction using multivariable logistic regression. The added value of ITH in the Final Combined Model was evaluated. Results: This study enrolled 368 patients, with 45.9% (169/368) having HER2-low breast cancer. The ITH score was higher in HER2 low than that in HER2 zero (P<0.001), but lower than that in HER2 positive (P<0.001). The ITH score was higher in HER2 positive compared to HER2 zero (P<0.001). The Final Combined Model integrating ITH, MRI, and clinicopathological variables achieved good predictive performance, achieving area under the curve (AUC) values of 0.80 [95% confidence interval (CI): 0.75-0.86] for HER2 low Conclusions: Integrating ITH from high-spatial resolution UF DCE-MRI-based kinetic curves improved the non-invasive differentiation of HER2-low breast cancer. This approach may guide targeted biopsy strategies and aid in selecting candidates for anti-HER2 ADC therapy, optimizing HER2-targeted precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.